FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.
MIAMI, April 25, 2022 /PRNewswire/ -- Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022. TLANDO® is an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone in adult males.
TLANDO® was developed by Lipocine Inc., a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders. Lipocine has granted Antares Pharma an exclusive license to commercialize TLANDO® in the U.S.
"The entire Brand Institute and Drug Safety Institute Team congratulates Antares Pharma and Lipocine on the FDA approval of TLANDO," said Brand Institute's Chairman and C.E.O., James L. Dettore.
About Brand Institute and our wholly owned regulatory subsidiary, Drug Safety Institute
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-tlando-testosterone-undecanoate-an-oral-treatment-for-testosterone-replacement-therapy-by-antares-pharma-inc-developed-by-lipocine-inc-301531980.html
SOURCE Brand Institute, Inc.